Published online Aug 15, 2025. doi: 10.4239/wjd.v16.i8.106215
Revised: March 28, 2025
Accepted: June 24, 2025
Published online: August 15, 2025
Processing time: 176 Days and 7.7 Hours
Lower limb atherosclerotic occlusive disease (LAOD) is a common complication in diabetic patients, leading to significant symptoms and reduced quality of life.
To investigate the efficacy of autologous platelet-rich gel (APRG) as an innovative treatment for LAOD, focusing on clinical outcomes such as symptom relief, flow values, ankle-brachial index (ABI), walking distance, and claudication severity.
This retrospective study involved an analysis of electronic medical records (EMR) from 150 patients diagnosed with LAOD. Participants were assigned to either a treatment group (n = 80) or a control group (n = 70). Both groups received standard care and underwent dressing changes. In addition, the treatment group was given APRG. Primary outcomes included changes in pain levels, wound healing rates, flow values assessed by plethysmography, ABI measurements, walking distance, and claudication severity. Statistical analyses were conducted to determine the significance of the results.
The APRG group showed significant improvements after 12 weeks, including a 70% reduction in pain, a 65% increase in wound healing rates, and an average walking distance increase of 150 meters. Flow values improved by 20%, with significant enhancements in ABI measurements (P < 0.01). Additionally, patient satisfaction was higher, and 60% of patients reported improved claudication severity, confirming the efficacy of APRG in enhancing clinical outcomes for lower LAOD.
The APRG demonstrates significant efficacy in managing LAOD in diabetic patients, improving key clinical parameters including flow values, ABI, walking distance, and claudication. These findings support the need for further prospective studies to validate long-term efficacy and optimize treatment strategies.
Core Tip: This study investigates the innovative application of autologous platelet-rich gel (APRG) for the treatment of lower limb atherosclerotic occlusive disease (LAOD) in diabetic patients. A retrospective analysis involving 150 patients demonstrated that APRG significantly enhanced clinical outcomes, including a 70% reduction in pain, a 65% increase in wound healing rates, and an improvement in walking distance by 150 meters after 12 weeks. These promising results indicate that APRG may serve as a transformative treatment option for diabetic patients suffering from LAOD. Further prospective studies are essential to validate its long-term efficacy and safety in this population.